BidaskClub lowered shares of Clovis Oncology (NASDAQ:CLVS) from a hold rating to a sell rating in a research report report published on Wednesday.
CLVS has been the subject of several other reports. ValuEngine downgraded shares of Clovis Oncology from a hold rating to a sell rating in a research report on Wednesday, January 2nd. Zacks Investment Research raised shares of Clovis Oncology from a sell rating to a hold rating in a research report on Thursday, January 24th. Leerink Swann raised shares of Clovis Oncology from a market perform rating to an outperform rating in a research report on Tuesday, December 4th. Oppenheimer reaffirmed a hold rating on shares of Clovis Oncology in a research report on Tuesday, October 30th. Finally, SunTrust Banks downgraded shares of Clovis Oncology to a buy rating and upped their price objective for the stock from $20.00 to $70.00 in a research report on Wednesday, October 31st. Three research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $54.96.
NASDAQ:CLVS opened at $24.24 on Wednesday. The company has a quick ratio of 8.46, a current ratio of 9.03 and a debt-to-equity ratio of 2.46. The stock has a market cap of $1.28 billion, a PE ratio of -4.73 and a beta of 2.14. Clovis Oncology has a one year low of $11.50 and a one year high of $65.24.
In other news, insider Lindsey Rolfe sold 1,728 shares of the stock in a transaction that occurred on Thursday, December 20th. The shares were sold at an average price of $17.72, for a total transaction of $30,620.16. Following the completion of the transaction, the insider now directly owns 17,600 shares of the company’s stock, valued at approximately $311,872. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.20% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in CLVS. Samlyn Capital LLC bought a new position in shares of Clovis Oncology during the 4th quarter valued at approximately $18,054,000. Orbimed Advisors LLC grew its position in shares of Clovis Oncology by 23.2% during the 4th quarter. Orbimed Advisors LLC now owns 2,752,200 shares of the biopharmaceutical company’s stock valued at $49,430,000 after acquiring an additional 517,630 shares during the period. Alliancebernstein L.P. grew its position in shares of Clovis Oncology by 48.4% during the 3rd quarter. Alliancebernstein L.P. now owns 1,414,652 shares of the biopharmaceutical company’s stock valued at $41,548,000 after acquiring an additional 461,629 shares during the period. Elk Creek Partners LLC bought a new position in shares of Clovis Oncology during the 4th quarter valued at approximately $6,828,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Clovis Oncology during the 4th quarter valued at approximately $5,641,000. 99.71% of the stock is owned by hedge funds and other institutional investors.
Clovis Oncology Company Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Featured Article: How a Back-End Load Mutual Fund Works
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.